Janux Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Janux Therapeutics

05/05/2025 22:06

Janux Therapeutics Inc JANX.OQ JANX.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The San Diego California-based  company is expected to report a 55.1% decrease in revenue to $562.5 thousand from $1.25 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Janux Therapeutics Inc is for a loss of 39 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Janux Therapeutics Inc is $76.00​, above​ its last closing price of $32.88. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.47
-0.46
-0.36
Beat
21
Sep. 30 2024
-0.30
-0.33
-0.51
Missed
-55.7
Jun. 30 2024
-0.29
-0.31
-0.11
Beat
65​
Mar. 31 2024
-0.32
-0.33
-0.30
Beat
9.4
​​Dec. 31 2023
-0.38
-0.39
-0.25
Beat
36.3
Sep. 30 2023
-0.45
-0.47
-0.25
Beat
46.8​
Jun. 30 2023
-0.50
-0.52
-0.42
Beat
18.8
Mar. 31 2023
-0.49
-0.49
-0.42
Beat
14.6

This summary was machine generated May 5 at 21:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)